Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
Sponsor: RenJi Hospital
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Official title: NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-02
Completion Date
2031-09
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Interventions
Serplulimab
1.5mg/kg qw, start from C1D15
Paclitaxel
80mg/m\^2 qw
Carboplatin
AUC=1.5, D1, 8, 15, every 28 days
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China